McKesson Corporation (MCK)
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
McKesson (MCK) reached $976.57 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
McKesson (MCK) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why McKesson (MCK) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
Here is how McKesson (MCK) and Avantor, Inc. (AVTR) have performed compared to their sector so far this year.
Is It Worth Investing in McKesson (MCK) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Here's Why McKesson (MCK) Fell More Than Broader Market
In the closing of the recent trading day, McKesson (MCK) stood at $910.33, denoting a -1.23% move from the preceding trading day.
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
McKesson and CD&R agree to acquire Option Care Health for $5.8 billion
Mckesson Corp (NYSE:MCK), the US healthcare services and drug distribution company, and Clayton Dubilier & Rice (CD&R), the private investment firm, have agreed to acquire Option Care Health (NASDAQ:OPCH) for approximately $5.8 billion. The buyers will pay $32.05 a share for Option Care Health, the largest independent provider of home and alternate-site infusion services in the US, representing a 37% premium to Monday's closing price.
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
Under the agreement, CD&R will hold a majority interest of about 51% in Option Care Health, while McKesson will hold about 49%.
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.
